Status:
COMPLETED
Multihance at 3 Tesla (3T) in Brain Tumors
Lead Sponsor:
Bracco Diagnostics, Inc
Conditions:
Brain Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Compare the efficacy of MultiHance and Magnevist
Detailed Description
The purpose of this study was to evaluate whether Multihance is superior to Magnevist in terms of qualitative and quantitative assessment of unenhanced MRI and contrast-enhanced MRI for the visualizat...
Eligibility Criteria
Inclusion
- Was 18 years or older
- Provided written informed consent
- Scheduled for MRI
- Confirmed or highly suspected to have brain tumor(s) and willing to undergo two MRI exams within 14 days
Exclusion
- Pregnant or lactating females
- Allergy to one or more of the ingredients in the products or hypersensitivity to any metals
- Congestive heart failure, class IV
- Previous stroke in the past year
- Received another contrast agent within 24 hours pre and post each exam
- Investigational product
- Contraindications to MRI
- Severe claustrophobia
- Surgery with 3 weeks prior
- Steroid therapy or radiosurgery between two exams
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00395863
Start Date
November 1 2006
End Date
March 1 2008
Last Update
November 5 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bracco Diagnostics, Inc.
Princeton, New Jersey, United States, 08540